KURA · XBRL financial data

Kura Oncology financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (KURA's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	—	—	—	0	54	67
Research and development	60	85	93	115	170	251
Selling, general and administrative	—	—	—	51	77	120
General and administrative	32	47	47	51	77	—
Total operating expenses	92	131	140	166	247	371
Operating income (loss)	—	—	(140)	(166)	(193)	(304)
Interest expense	1	0	0	2	2	2
Income tax expense (benefit)	0	0	0	0	2	0
Net income (loss)	(90)	(130)	(136)	(153)	(174)	(279)
Earnings per share, basic USD per share	(1.69)	(1.97)	(2.03)	(2.08)	(2.02)	(3.18)
Earnings per share, diluted USD per share	(1.69)	(1.97)	(2.03)	(2.08)	(2.02)	(3.18)
Weighted average shares, basic millions of shares	53	66	67	73	86	88
Weighted average shares, diluted millions of shares	53	66	67	73	86	88

Fiscal years (KURA's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	325	91	52	37	224	149
Marketable securities	308	427	386	387	503	518
Accounts receivable	—	—	—	—	2	9
Inventory	—	—	—	—	0	0
Prepaid and other current assets	4	4	8	9	17	32
Total current assets	637	522	446	432	745	709
Property and equipment, net	2	3	3	2	2	8
Right-of-use asset	6	6	4	7	6	7
Total assets	647	534	456	449	760	738
Accounts payable	3	3	2	2	1	5
Accrued liabilities	—	17	—	—	—	—
Current portion of long-term debt	3	—	—	—	3	0
Total current liabilities	26	22	24	35	79	117
Long-term debt	4	—	9	9	7	10
Lease liability, non-current	6	5	3	6	5	9
Total liabilities	36	27	36	52	347	564
Accumulated deficit	(303)	(433)	(569)	(721)	(895)	(1,174)
Total stockholders' equity	611	507	420	397	414	174
Total liabilities and equity	647	534	456	449	760	738
Common shares outstanding (cover page) millions of shares	66	67	68	76	81	88

Fiscal years (KURA's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(90)	(130)	(136)	(153)	(174)	(279)
Stock-based compensation	13	24	26	28	34	37
Net cash from operating activities	(70)	(105)	(110)	(125)	134	(64)
Purchases of property and equipment	2	1	1	0	0	7
Net cash from investing activities	(100)	(127)	33	16	(102)	(13)
Proceeds from issuing common stock	459	—	25	—	—	—
Proceeds from long-term debt	—	—	10	—	—	—
Repayments of long-term debt	0	7	—	—	—	—
Net cash from financing activities	469	(3)	39	95	154	2
Net change in cash	300	(235)	(39)	(14)	187	(75)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Kura Oncology	70	21	(63)*	89.0M	8.3 quarters	Q2 FY26 10-QJun 30, 2026
Myriad Genetics	115	191	(8.3)*	95.6M	13.9 quarters	Q2 FY26 10-QJun 30, 2026
KalVista Pharmaceuticals	214	41	(14)	53.2M	19.7 quarters	Q1 FY26 10-QMar 31, 2026
Arbutus Biopharma	19	1	(6)*	197.8M	15.4 quarters	Q2 FY26 10-QJun 30, 2026
Arvinas	88	0.5	(10)*	65.5M	13.0 quarters	Q3 FY26 10-QSep 30, 2026
aTYR PHARMA	16	not reported	(9.4)*	98.1M	6.1 quarters	Q2 FY26 10-QJun 30, 2026
Elite Pharmaceuticals	39	32	10	1.1B	—	Q1 FY27 10-QJun 30, 2026
Iovance Biotherapeutics	111	99	(61)*	453.0M	4.9 quarters	Q2 FY26 10-QJun 30, 2026
Opko Health	384	65	(36)*	742.5M	10.8 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.